company background image
VSTM logo

Verastem NasdaqCM:VSTM Stock Report

Last Price

US$4.19

Market Cap

US$186.5m

7D

-10.5%

1Y

-49.3%

Updated

23 Dec, 2024

Data

Company Financials +

My Notes

Capture your thoughts, links and company narrative

Verastem, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Verastem
Historical stock prices
Current Share PriceUS$4.19
52 Week HighUS$14.22
52 Week LowUS$2.10
Beta0.22
1 Month Change4.75%
3 Month Change56.34%
1 Year Change-49.27%
3 Year Change-84.34%
5 Year Change-75.24%
Change since IPO-96.85%

Recent News & Updates

Recent updates

Verastem: Narrowed Market And Less Compelling Efficacy Warrant Rating Downgrade

May 26

Verastem: Moving Forward

Sep 13

Health Check: How Prudently Does Verastem (NASDAQ:VSTM) Use Debt?

Sep 01
Health Check: How Prudently Does Verastem (NASDAQ:VSTM) Use Debt?

Verastem Non-GAAP EPS of -$0.11 in-line

Aug 08

Verastem: Looking Increasingly Attractive

Jun 29

Verastem: Time To Take My Position Out Of Mothball

Apr 19

Vectoring In On Verastem

Jan 12

Verastem: Buying Opportunity Following Unjustified Sell-Off

Sep 22

Shareholder Returns

VSTMUS BiotechsUS Market
7D-10.5%-3.8%-2.7%
1Y-49.3%-2.6%23.4%

Return vs Industry: VSTM underperformed the US Biotechs industry which returned -2.6% over the past year.

Return vs Market: VSTM underperformed the US Market which returned 23.4% over the past year.

Price Volatility

Is VSTM's price volatile compared to industry and market?
VSTM volatility
VSTM Average Weekly Movement14.7%
Biotechs Industry Average Movement10.7%
Market Average Movement6.3%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: VSTM's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: VSTM's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201073Dan Patersonwww.verastem.com

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205.

Verastem, Inc. Fundamentals Summary

How do Verastem's earnings and revenue compare to its market cap?
VSTM fundamental statistics
Market capUS$186.48m
Earnings (TTM)-US$93.45m
Revenue (TTM)US$10.00m

18.6x

P/S Ratio

-2.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
VSTM income statement (TTM)
RevenueUS$10.00m
Cost of RevenueUS$0
Gross ProfitUS$10.00m
Other ExpensesUS$103.45m
Earnings-US$93.45m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-2.10
Gross Margin100.00%
Net Profit Margin-934.54%
Debt/Equity Ratio126.2%

How did VSTM perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 10:34
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Verastem, Inc. is covered by 27 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James MolloyAlliance Global Partners
Matthew CrossAlliance Global Partners
Kalpit PatelB. Riley Securities, Inc.